Aysegul Bilgic
About Aysegul Bilgic
Aysegul Bilgic is the Strategy and Operations Lead for the CEEME region at Bristol-Myers Squibb, with over 20 years of experience in the pharmaceutical industry, including extensive roles in oncology and haematology.
Title and Current Role at Bristol-Myers Squibb
Aysegul Bilgic currently holds the title of Strategy and Operations Lead for the CEEME region at Bristol-Myers Squibb, based in London, Greater London, United Kingdom. She also serves as a Business Unit Director at the same company. Aysegul's role involves key strategic planning and operational tasks aimed at enhancing the company's regional objectives.
Career at Novartis and GlaxoSmithKline
Before joining Bristol-Myers Squibb, Aysegul worked as Business Franchise Head - Oncology at Novartis from 2015 to 2016 in Basel, Switzerland. Prior to that, she was employed at GlaxoSmithKline, where she held multiple roles including Business Unit Manager - Oncology and Haematology from 2013 to 2015, Business Unit Manager - Primary Care from 2011 to 2012, and Group Product Manager - Primary Care from 2009 to 2010.
Experience at Lundbeck
Aysegul Bilgic began her pharmaceutical career at Lundbeck, serving in various roles. She started as a Project Manager - Sales and Marketing Excellence from 1999 to 2003, before transitioning to Product Manager from 2003 to 2006. In 2007, she worked as an International Brand Manager - Neurology based in Denmark, followed by a role as Group Product Manager - Neurology from 2008 to 2009.
Expertise in Oncology and Haematology
With a career spanning over 20 years, Aysegul Bilgic has extensive expertise in oncology and haematology. This specialization has been reinforced by her roles at GlaxoSmithKline and Novartis, where she led various initiatives focusing on these fields. Her deep domain knowledge has made her a valuable asset in multiple pharmaceutical companies.
International Work Experience
Aysegul Bilgic's professional journey includes substantial international experience. Notably, she held positions in Basel, Switzerland, and Denmark during her tenure at Novartis and Lundbeck, respectively. This international exposure has equipped her with a diverse perspective and a robust understanding of global pharmaceutical markets.